Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC

NCT05898373 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Salivary Gland Cancer

Interventions

DRUG: vedicitumomab (Edisil, RC48）
DRUG: vedicitumomab in combination with pyrrolizidine
DRUG: RC48 in combination with a platinum-based chemotherapeutic agent
DRUG: RC48 in combination with teraplizumab

Sponsor

Peking Union Medical College